[BizHanKook] Heidelberg, located in the state of Baden-Württemberg in southwestern Germany, is primarily known to Koreans as a "romantic university city with an old castle." The Old Town formed along the Neckar River, Heidelberg Castle on the hill, and the Philosopher's Walk attract countless tourists every year. Thanks to escaping large-scale bombing during World War II, unlike other major German cities, its historical cityscape remains relatively intact.
Today, the force driving Heidelberg is not just tourism. This city of approximately 160,000 residents is a leading scientific and medical research hub in Germany and a major European life sciences cluster. It is densely packed with institutions such as the German Cancer Research Center (DKFZ), the European Molecular Biology Laboratory (EMBL), Heidelberg University and its hospital, the Max Planck Institute, and numerous global pharmaceutical companies and bio-startups.
Heidelberg's competitiveness does not lie solely in the reputation of individual institutions. The key is the interconnected structure established within the city, where discoveries made in basic research move into hospitals and clinical settings, eventually leading to the development of new drugs, diagnostic technologies, and medical devices by companies.
A City of Learning Since 1386
The name of the city of Heidelberg first appeared in literature at the end of the 12th century. It later grew into a base city for the Electors Palatine, and in 1386, Elector Rupert I founded Heidelberg University. Its official name, Ruprecht-Karls-Universität Heidelberg, is the oldest university in Germany. Even today, Heidelberg University is recognized as one of Germany's representative research-oriented universities.
Not every city with an old university becomes an innovation cluster. The characteristic of Heidelberg is that modern medical infrastructure and international research institutions were added after the war on top of a foundation of medical and natural science research accumulated over hundreds of years.
The city's research functions are not limited to university buildings in the Old Town. Across the Neckar River, the Neuenheimer Feld houses the university's natural science and medical campus, the university hospital, the German Cancer Research Center, and various other research institutions. Here, university professors, clinicians, researchers, and company representatives work in close physical proximity. It is an environment favorable to narrowing the gap between basic research and clinical reality, which is especially important in the bio-industry.
BioRN: Germany's Largest Bio-Life Science Cluster
The organization representing the life science ecosystem in the Heidelberg and Rhine-Neckar region is the BioRN Life Science Cluster. Launched in 1996 and celebrating its 30th anniversary this year, BioRN is not a university or a research institute, but a cluster organization that connects local companies, research institutions, hospitals, investors, and startup support agencies.
The Rhine-Neckar region is home to approximately 1,200 life science companies, over 15 major research institutions, and about 14,000 scientific personnel. Furthermore, seven of the world's top 10 pharmaceutical companies by revenue have bases in this region. BioRN itself has over 180 members. The BioRN member network includes not only research and medical institutions like Heidelberg University, Heidelberg University Hospital, EMBL, and DKFZ, but also major corporations such as AbbVie, BASF, Bayer, and Boehringer Ingelheim. Biotech firms, Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs), investment firms, and companies specializing in patents, regulations, and business development are also part of it.
BioRN’s role goes beyond hosting simple networking events. It provides the "BioRN Scout" to find researchers and startups that match the technological needs of companies, "soft-landing" services to support foreign companies entering Germany and Europe, and startup support and investor matching. BioLabs Heidelberg, a shared wet-lab space that early-stage bio-companies can utilize, was also attracted through BioRN's initiative.
For bio-startups, a laboratory holds a completely different meaning than a standard office space. If one has to set up expensive equipment and safety facilities independently, significant capital is required before even starting the business. A shared laboratory reduces initial fixed costs while simultaneously acting as a hub that brings similar-stage companies, researchers, and investors into one space. BioRN is more like an ecosystem operator that connects research results to startups, investments, and technology transfers, rather than just an organization listing research institutions.
The Role of the EU Joint Research Institution: EMBL
The European Molecular Biology Laboratory (EMBL) is a representative institution that demonstrates the international nature of the Heidelberg life science ecosystem. EMBL is an intergovernmental research organization jointly operated by several member states, with its headquarters and major research facilities located in Heidelberg.
It currently operates six hubs, including Heidelberg, Hinxton (UK), Grenoble (France), Hamburg (Germany), Rome (Italy), and Barcelona (Spain). Its research areas cover a wide range of core modern life science domains such as cell biology, genomics, structural biology, bioinformatics, imaging, and tissue biology.
EMBL's role does not end with producing papers. It provides advanced research equipment and data infrastructure to the scientific community, conducts researcher training, and performs international joint research. Its technology transfer subsidiary, EMBLEM, manages intellectual property originating from EMBL and supports corporate licensing and startup establishment. Having a separate specialized organization to connect basic research with commercialization is also a significant feature of the Heidelberg ecosystem.
German Cancer Research Center (DKFZ): Bridging Cancer Research and Clinical Practice
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany's largest biomedical research institute. Affiliated with the Helmholtz Association, it researches the causes, risk factors, prevention, diagnosis, and treatment of cancer. More than 3,000 personnel work here, researching cell and tumor biology, genomics, immunology, imaging and radiation oncology, and epidemiology and cancer prevention. DKFZ places core emphasis on translational research that connects research results to patient treatment.
An institution symbolizing this is the National Center for Tumor Diseases (NCT) in Heidelberg. In cooperation with DKFZ and Heidelberg University Hospital, researchers and clinicians jointly develop precise diagnostics, clinical trials, and new cancer treatments. It is a structure where biomarkers or therapeutic targets discovered in the lab can be verified in collaboration with the hospital to see if they can be applied to actual patients.
From the perspective of Korean bio-startups, DKFZ and the university hospital are not merely high-profile research institutions. For new cancer diagnostic technologies or drug candidates to enter the European market, they need clinical necessity, access to patient samples, verification with local medical staff, and regulatory strategy. In Heidelberg, one can find researchers, hospitals, clinical experts, and commercialization partners to support these processes in relatively close proximity.
Germany’s Oldest Tradition of Medical Education
Heidelberg University Hospital is often called the "oldest university hospital in Germany," but it is more accurate to describe it as a university hospital that carries on the medical education tradition of Germany's oldest university. The history of Heidelberg University's Faculty of Medicine dates back to 1388. It is well-known to the public through the representative film "Anatomie," which is set in the university and its anatomy laboratory.
Today, the Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is a leading German university hospital that carries out patient care, research, and medical education simultaneously. It is particularly strong in the fields of cancer, rare diseases, neuroscience, cardiovascular diseases, and complex, severe illnesses. It conducts joint research with external institutions including the DKFZ and validates developed treatments within the hospital.
Heidelberg’s strength lies in more than just the "existence" of research institutions around the hospital. The laboratories and hospitals create joint organizations like the NCT, where researchers and clinicians work together on a single project, and connect achievements to technology transfers or startups. It is an approach that views science, medicine, and industry as one continuous value chain.
A Daily Life Sphere Extending to Mannheim and Ludwigshafen
The Heidelberg life science cluster does not end within the city’s administrative boundaries. Mannheim is about 15 minutes away by train from Heidelberg, and across the Rhine River lies Ludwigshafen, home to the headquarters of BASF, one of the world's largest chemical companies. The three cities form a single living and industrial zone known as the Rhine-Neckar metropolitan region.
Mannheim complements Heidelberg in the fields of medical technology and clinical practice. Notably, Heidelberg University houses two medical faculties: the Heidelberg Medical Faculty and the Mannheim Medical Faculty. The Mannheim Medical Faculty is closely integrated with the University Medical Center Mannheim to carry out research and medical education.
Although the operating structures of the Heidelberg University Hospital and the University Medical Center Mannheim are distinct, both medical faculties belong to Heidelberg University, and they conduct research, education, and clinical cooperation within the metropolitan area. Consequently, a single university has secured two medical hubs with different strengths.
Another example showing regional connection is 5-HT Chemistry & Health. Based in Ludwigshafen, 5-HT connects companies, startups, investors, and research institutions in the chemical and healthcare sectors. BASF, SAP, and startup support agencies from the Rhine-Neckar region and the Mannheim-Heidelberg-Ludwigshafen area are participating as shareholders.
In this structure, Heidelberg provides strengths in universities and basic/clinical research; Mannheim provides medical technology and industrial applications; and Ludwigshafen provides the chemical and materials industry. Intermediate organizations like BioRN and 5-HT connect the necessary partners, transcending the boundaries between cities and industries.
Korean Bio-Startups in Heidelberg
On September 17, the "K-Biotech Innovation Day" was held at the Heidelberg Business Development Center. The event was hosted by IBK Changgong Daegu, Y&Archer, and 123Factory, with BioRN participating as a local partner.
On this day, Korean bio-medtech startups introduced their technologies to research institutions, clinical/business development experts, and company officials in the BioRN ecosystem. The participating companies presented their major needs, such as clinical and joint research partners, distribution partners, opportunities for technology transfer and licensing, and strategic business cooperation.
First, AAVATAR Therapeutics is a gene therapy platform company that designs AAV capsids using artificial intelligence to deliver genes more accurately and safely to specific tissues. It received the most enthusiastic attention on the spot that day.
AIT STUDIO is a digital healthcare company that quantifies a patient's movement and functional state through AI-based gait analysis. The interest from local institutions was immense, to the point where they secured a equipment purchase contract for PoC not only with the Fraunhofer Institute but also with Berlin’s Charité University Hospital, Europe’s largest university hospital.
BICHEDAM is a bio-company developing oral therapeutic agents based on natural materials. CEO Moon Ho-bin, a former oriental medicine doctor, participated in the program with such passion that he closed his clinic to dedicate himself to herbal-based drug development. Locally, the company attracted interest from global pharmaceutical firms like GSK and discussed joint research and development with the Sports Medicine Research Institute at Goethe University Frankfurt.
BeyondDx is a diagnostic technology company that discovers diseases early by combining artificial intelligence and multi-omics data. It was founded by CEO Jung So-jin, who went through business strategy, strategic planning, and business development after starting with R&D for therapeutics at domestic conglomerates like CJ, SK Chemicals, and Chong Kun Dang. On this day, Executive Director Kim Hyun-pyo pitched passionately to find local joint R&D partners in Germany.
LMNTIC Biotech is a liquid biopsy platform company that separates and analyzes circulating tumor cells in blood using micro-magnetophoresis technology. Co-founder and CSO Baek Seo-rim skillfully built networking based on her deep understanding of the region, stemming from her eight years of living in Germany.
Although their technical fields were different, these companies shared a common task: they had to answer how the research results and products secured in Korea would be connected to clinical problems in the European market, who would verify the technology and conduct joint research, and in which country they would create their first commercialization case.
The overseas expansion of bio-companies does not happen just by participating in exhibitions or establishing a local branch. Even if one has good technology, local medical staff and researchers must acknowledge the necessity of that technology, and joint verification results must be created. Afterward, a long process follows, leading to regulations, clinical trials, investment, licensing, or distribution.
In that sense, the presentation at BioRN is not the completion of entry into Europe, but the starting point. After the presentation, it is more important which researchers will engage in follow-up discussions, which hospital will start a small verification project, and how those results will be connected to local business development.
Heidelberg has world-class universities, hospitals, and research institutions. However, it is difficult to explain today's bio-cluster by those names alone. Heidelberg's real competitiveness is the fact that the structure in which research institutions, hospitals, startups, pharmaceutical companies, and investors can meet has been accumulated over a long period.
BioRN finds and connects the necessary partners, and BioLabs provides experimental space for early-stage companies. EMBL and DKFZ produce world-class research and technology, and the university hospital connects this to the clinical field. Adjacent Mannheim and Ludwigshafen contribute the foundations of medical technology and the chemical/materials industry.
There are quite a few regions in Korea where excellent hospitals, research institutions, and bio-companies are concentrated. However, to become a world-class bio-cluster, it requires more than just the number of institutions; it requires the path for research results to move to hospitals and companies, a window for overseas companies to find appropriate partners, and operational capabilities to develop small joint verification projects into actual contracts and investments.
The author Lee Eun-seo majored in law in Korea and studied theater in Berlin. Based in Berlin, a city of art and a European startup hub, she leads 123Factory, growing alongside the city and connecting the startup ecosystems of Korea and Germany.